OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Jennifer Pritzker Sells 10,131 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Jennifer Pritzker sold 10,131 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.10, for a total transaction of $234,026.10. Following the completion of the sale, the insider directly owned 6,526,633 shares in the company, valued at approximately $150,765,222.30. The trade was a 0.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

OrthoPediatrics Trading Down 1.3%

Shares of NASDAQ:KIDS opened at $23.00 on Wednesday. OrthoPediatrics Corp. has a 52-week low of $14.42 and a 52-week high of $26.74. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. The company has a market capitalization of $600.53 million, a P/E ratio of -13.69 and a beta of 0.98. The company has a 50-day simple moving average of $21.61 and a 200 day simple moving average of $18.76.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Sell-side analysts forecast that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Key Stories Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Analysts assigned OrthoPediatrics a consensus price target of $26.44, implying potential upside from recent trading levels and signaling continued confidence in the company’s long-term growth prospects. OrthoPediatrics Receives $26.44 Consensus Price Target
• Neutral Sentiment: The reported sales appear across related director, major-shareholder and beneficial-ownership filings, meaning some transactions may represent overlapping disclosures rather than entirely separate blocks of stock. After the transactions, the reporting holders still controlled approximately 6.53 million shares, indicating continued substantial exposure to KIDS. SEC Insider Transaction Filing
• Negative Sentiment: Director David R. Pelizzon and major shareholder Jennifer N. Pritzker reported sales of 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. Each reduced their reported ownership by 4.76%, which may pressure the stock or raise concerns about insider confidence, although both retained large positions. SEC Major Shareholder Ownership Filing
• Negative Sentiment: The same holders, along with Squadron Capital LLC, reported additional sales of 10,131 shares on September 1 at $23.10, worth approximately $234,000 per reported transaction. The small 0.15% ownership reduction is less significant by itself, but reinforces the near-term insider-selling overhang. SEC Ownership Filing

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Truist Financial set a $22.00 price target on OrthoPediatrics in a research note on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Needham & Company LLC upped their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Finally, BTIG Research raised their target price on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.44.

Hedge Funds Weigh In On OrthoPediatrics

Large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its holdings in OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the last quarter. Legal & General Group Plc bought a new stake in OrthoPediatrics in the 2nd quarter valued at $34,000. Northwestern Mutual Wealth Management Co. grew its holdings in OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after buying an additional 2,561 shares in the last quarter. Caption Management LLC acquired a new position in OrthoPediatrics in the 3rd quarter valued at $54,000. Finally, BNP Paribas Financial Markets increased its position in OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after buying an additional 1,235 shares during the period. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.